- Home
- AURA
as 07-26-2024 4:00pm EST
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 429.5M | IPO Year: | 2021 |
| Target Price: | $21.00 | AVG Volume (30 days): | 220.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.99 - $12.44 | Next Earning Date: | 08-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Aura Biosciences Inc. (AURA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| de los Pinos Elisabet | AURA | See Remarks | Jan 23 '24 | Sell | $7.64 | 15,853 | $121,140.70 | 161,438 | SEC Form 4 |
| Feder Julie B | AURA | Chief Financial Officer | Jan 23 '24 | Sell | $7.64 | 6,609 | $50,521.18 | 62,991 | SEC Form 4 |
| Johnson David Michael | AURA | Director | Nov 7 '23 | Buy | $7.17 | 76,000 | $544,920.00 | 126,066 | SEC Form 4 |
| Johnson David Michael | AURA | Director | Nov 7 '23 | Buy | $7.17 | 47,000 | $336,990.00 | 65,000 | SEC Form 4 |
| Johnson David Michael | AURA | Director | Nov 7 '23 | Buy | $7.17 | 47,000 | $336,990.00 | 65,000 | SEC Form 4 |
| Johnson David Michael | AURA | Director | Nov 7 '23 | Buy | $7.30 | 9,601 | $70,087.30 | 135,667 | SEC Form 4 |
| Johnson David Michael | AURA | Director | Nov 7 '23 | Buy | $7.30 | 10,000 | $73,000.00 | 75,000 | SEC Form 4 |
| Johnson David Michael | AURA | Director | Nov 7 '23 | Buy | $7.30 | 10,000 | $73,000.00 | 75,000 | SEC Form 4 |
Latest Aura Biosciences Inc. News
AURA Breaking Stock News: Dive into AURA Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
HC Wainwright Starts Aura Biosciences With Buy Rating, $21 Price Target
Zacks
2 months ago
Wall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High?
GlobeNewswire
2 months ago
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
2 months ago
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024
GuruFocus.com
3 months ago
Aura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed Financial Overview
GlobeNewswire
3 months ago
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
3 months ago
Aura Biosciences to Participate in Upcoming Investor Conferences
Simply Wall St.
3 months ago
One Aura Biosciences Insider Raised Stake By 232% In Previous Year
Compare AURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AURA Aura Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.